Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G0401
- Development stage
- Preclinical
- Lead developer
- GeneSail Biotech
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
01
Overview
G0401 is an investigational oncolytic virus therapy being developed by GeneSail Biotech for the treatment of solid tumors. It utilizes a vaccinia virus vector engineered to selectively infect and lyse malignant cells while sparing normal tissue. This oncolytic process is intended to release tumor-associated antigens and provide a pro-inflammatory stimulus, thereby inducing a systemic antitumor immune response. As of early 2024, G0401 is in the preclinical stage of development, representing an earlier-stage candidate in GeneSail's pipeline of vaccinia-based oncolytic agents, following more advanced candidates such as G0306 and G0321.
Beyond the preview
Go deeper on G0401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G0401.